KyungAh Im

TL;DR: SGLT2i have moderate benefits on atherosclerotic major adverse cardiovascular events that seem confined to patients with established atheroscerotic cardiovascular disease, however, they have robust benefits on reducing hospitalisation for heart failure and progression of renal disease regardless of existing atherosclerosis or a history of heart failure.

TL;DR: The achieved absolute LDL-C level was significantly associated with the absolute rate of major coronary events, including coronary death or MI, for primary prevention trials and secondary prevention trials (1.5%-2.5% lower event rate); and for established nonstatin interventions that work primarily via upregulation of LDL receptor expression (ie, diet, bile acid sequestrants, ileal bypass, and ezetimibe).

TL;DR: GLP1-RA and SGLT2i reduce atherosclerotic MACE to a similar degree in patients with established atherosclerosis cardiovascular disease, whereas SGLG2i has a more marked effect on preventing hospitalization for heart failure and progression of kidney disease.

TL;DR: Treatment with saxagliptin improved ACR, even in the normoalbuminuric range, without affecting eGFR, and the beneficial effect of saxagLIptin on albuminuria could not be explained by its effect on glycemic control.

TL;DR: Reductions in total PEP events, driven by reductions in MI and stroke, more than doubled the number of events prevented compared with examining only the first event, and support continuation of intensive combination lipid-lowering therapy after an initial CV event.